title: Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
abstract: The goal of platelet function testing in the catheterization laboratory is to provide information about the platelet contributions to the risk of thrombotic or hemorrhagic events and optimization of anti-platelet therapy for percutaneous interventions. We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk.
authors.affiliation: Department of Cardiology, University of Michigan, Ann Arbor, Michigan 48109-0022, USA. dmukherjee@po.net
authors.forename: D
authors.initials: D
authors.lastname: Mukherjee
authors.forename: D P
authors.initials: DP
authors.lastname: Chew
authors.forename: M
authors.initials: M
authors.lastname: Robbins
authors.forename: J S
authors.initials: JS
authors.lastname: Yadav
authors.forename: R E
authors.initials: RE
authors.lastname: Raymond
authors.forename: D J
authors.initials: DJ
authors.lastname: Moliterno
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000601:surgery; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016893:Carotid Stenosis / Q000601:surgery; D000077144:Clopidogrel; D015897:Comorbidity; D001026:Coronary Artery Bypass; D004359:Drug Therapy, Combination; D005260:Female; D005340:Fibrinogen; D006083:Graft Occlusion, Vascular / Q000601:surgery; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008863:Microspheres; D010446:Peptide Fragments / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010976:Platelet Count; D010979:Platelet Function Tests / Q000295:instrumentation; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012008:Recurrence; D012306:Risk; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; C082835:thrombin receptor peptide (42-47); D005340:Fibrinogen; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab